Los afectos adversos gastrointestinales relacionados con antidiabticos son frecuentes, siendo la metformina, la acarbosa y los agonistas de GLP-1 los frmacos con una asociacin bien establecida
These authors contributed equally: Deshan Yin, Fei Li Rights and permissions Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material
Euglycemic diabetic ketoacidosis is another concern that may delay initiation or result in early discontinuation of SGLT2i therapy [4, 19]
Disruption can then lead to health symptoms, illness, and possibly disease